CD38 and plasma cell myeloma: Careful analysis of bone-marrow samples collected during the first clinical trials with daratumumab monotherapy (GEN501 and Sirius) showed that patients with a relatively high expression of CD38 by the myeloma cells had a higher likelihood of achieving a partial response or better, when compared to patients whose tumor cells had lower cell surface expression of CD38 [8].